nach oben

Current Neurology and Neuroscience Reports

Erschienen in:

01.07.2021 | Neurology of Systemic Diseases (J. Biller, Section Editor)

Infection Mitigation Strategies for Multiple Sclerosis Patients on Oral and Monoclonal Disease-Modifying Therapies

verfasst von: Tyler Ellis Smith, Ilya Kister

Erschienen in: Current Neurology and Neuroscience Reports | Ausgabe 7/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

The newer, higher-efficacy disease-modifying therapies (DMTs) for multiple sclerosis (MS)—orals and monoclonals—have more profound immunomodulatory and immunosuppressive properties than the older, injectable therapies and require risk mitigation strategies to reduce the risk of serious infections. This review will provide a systematic framework for infectious risk mitigation strategies relevant to these therapies.

Recent Findings

We classify risk mitigation strategies according to the following framework: (1) screening and patient selection, (2) vaccinations, (3) antibiotic prophylaxis, (4) laboratory and MRI monitoring, (5) adjusting dose and frequency of DMT, and (6) behavioral modifications to limit the risk of infection. We systematically apply this framework to the infections for which risk mitigations are available: hepatitis B, herpetic infections, progressive multifocal leukoencephalopathy, and tuberculosis. We also discuss up-to-date recommendations regarding COVID-19 vaccinations for patients on DMTs.

Summary

We offer a practical, comprehensive, DMT-specific framework of derisking strategies designed to minimize the risk of infections associated with the newer MS therapies.

Gold R, Rieckmann P, Chang P, Abdalla J. The long-term safety and tolerability of high-dose interferon beta-1a in relapsing-remitting multiple sclerosis: 4-year data from the PRISMS study. Eur J Neurol. 2005;12(8):649–56. https://doi.org/10.1111/j.1468-1331.2005.01083.x.CrossRefPubMed

Ford C, Goodman AD, Johnson K, Kachuck N, Lindsey JW, Lisak R, et al. Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate. Mult Scler. 2010;16(3):342–50. https://doi.org/10.1177/1352458509358088.CrossRefPubMedPubMedCentral

• Otero-Romero S, Sánchez-Montalvá A, Vidal-Jordana A. Assessing and mitigating risk of infection in patients with multiple sclerosis on disease modifying treatment. Expert Rev Clin Immunol. 2021:null-null. https://doi.org/10.1080/1744666X.2021.1886924. A thorough review examining the infectious risks associated with DMT use.

Ancau M, Berthele A, Hemmer B. CD20 monoclonal antibodies for the treatment of multiple sclerosis: up-to-date. Expert Opin Biol Ther. 2019;19(8):829–43. https://doi.org/10.1080/14712598.2019.1611778.CrossRefPubMed

Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):899–910. https://doi.org/10.1056/NEJMoa044397.CrossRefPubMed

Subei AM, Cohen JA. Sphingosine 1-phosphate receptor modulators in multiple sclerosis. CNS Drugs. 2015;29(7):565–75. https://doi.org/10.1007/s40263-015-0261-z.CrossRefPubMedPubMedCentral

Yadav SK, Soin D, Ito K, Dhib-Jalbut S. Insight into the mechanism of action of dimethyl fumarate in multiple sclerosis. J Mol Med (Berl). 2019;97(4):463–72. https://doi.org/10.1007/s00109-019-01761-5.CrossRef

Ruck T, Bittner S, Wiendl H, Meuth SG. Alemtuzumab in multiple sclerosis: mechanism of action and beyond. Int J Mol Sci. 2015;16(7):16414–39. https://doi.org/10.3390/ijms160716414.CrossRefPubMedPubMedCentral

Bar-Or A, Pachner A, Menguy-Vacheron F, Kaplan J, Wiendl H. Teriflunomide and its mechanism of action in multiple sclerosis. Drugs. 2014;74(6):659–74. https://doi.org/10.1007/s40265-014-0212-x.CrossRefPubMedPubMedCentral

10.

Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann P, Sørensen PS, et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med. 2010;362(5):416–26. https://doi.org/10.1056/NEJMoa0902533.CrossRefPubMed

11.

Lim JK, Nguyen MH, Kim WR, Gish R, Perumalswami P, Jacobson IM. Prevalence of chronic hepatitis b virus infection in the United States. Official journal of the American College of Gastroenterology | ACG. 2020;115(9).

12.

Seto WK, Chan TS, Hwang YY, Wong DK, Fung J, Liu KS, et al. Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma: a prospective study. J Clin Oncol. 2014;32(33):3736–43. https://doi.org/10.1200/jco.2014.56.7081.CrossRefPubMed

13.

Yeo W, Chan TC, Leung NWY, Lam WY, Mo FKF, Chu MT, et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis b undergoing anticancer therapy with or without rituximab. J Clin Oncol. 2009;27(4):605–11. https://doi.org/10.1200/jco.2008.18.0182.CrossRefPubMed

14.

Ocrevus (Ocrelizumab) [Prescribing Information]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761053lbl.pdf. Revised March 2017. Accessed March 9, 2021.

15.

Ciardi MR, Iannetta M, Zingaropoli MA, Salpini R, Aragri M, Annecca R, et al. Reactivation of hepatitis b virus with immune-escape mutations after ocrelizumab treatment for multiple sclerosis. Open Forum Infect Dis. 2019;6(1):ofy356. https://doi.org/10.1093/ofid/ofy356.CrossRefPubMed

16.

Ogawa E, Wei MT, Nguyen MH. Hepatitis B Virus Reactivation Potentiated by Biologics. Infect Dis Clin N Am. 2020;34(2):341–58. https://doi.org/10.1016/j.idc.2020.02.009.CrossRef

17.

Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560–99. https://doi.org/10.1002/hep.29800.CrossRefPubMedPubMedCentral

18.

Rituxan (Rituximab). [Prescribing Information]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/103705s5311lbl.pdf. Revised February 2010. Accessed March 11, 2021.

19.

Kesimpta (Ofatumumab). [Prescribing Information]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125326s070lbl.pdf. Revised August 2020. Accessed March 11, 2021.

20.

Schillie S, Vellozzi C, Reingold A, Harris A, Haber P, Ward JW, et al. Prevention of hepatitis B virus infection in the united states: recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep. 2018;67(1):1–31. https://doi.org/10.15585/mmwr.rr6701a1.CrossRefPubMedPubMedCentral

21.

Mavenclad (Cladribine) [Prescribing Information]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022561s000lbl.pdf. Revised March 2019. Accessed March 17, 2021.

22.

Lu M-C, Shih Y-L, Hsieh T-Y, Lin J-C. Flare of hepatitis B virus after fingolimod treatment for relapsing and remitting multiple sclerosis. J Formos Med Assoc. 2020;119(4):886–7. https://doi.org/10.1016/j.jfma.2019.10.012.CrossRefPubMed

23.

Hillen ME, Cook SD, Samanta A, Grant E, Quinless JR, Rajasingham JK. Fatal acute liver failure with hepatitis B virus infection during nataluzimab treatment in multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. 2015;2(2):e72. https://doi.org/10.1212/nxi.0000000000000072.CrossRefPubMedPubMedCentral

24.

Iannitto E, Minardi V, Calvaruso G, Mulè A, Ammatuna E, Di Trapani R, et al. Hepatitis B virus reactivation and alemtuzumab therapy. Eur J Haematol. 2005;74(3):254–8. https://doi.org/10.1111/j.1600-0609.2004.00375.x.CrossRefPubMed

25.

Arvin AM. Varicella-zoster virus. Clin Microbiol Rev. 1996;9(3):361–81. https://doi.org/10.1128/CMR.9.3.361-381.1996.CrossRefPubMedPubMedCentral

26.

Kennedy PG, Rovnak J, Badani H, Cohrs RJ. A comparison of herpes simplex virus type 1 and varicella-zoster virus latency and reactivation. J Gen Virol. 2015;96(Pt 7):1581–602. https://doi.org/10.1099/vir.0.000128.CrossRefPubMedPubMedCentral

27.

Ho DY, Enriquez K, Multani A. Herpesvirus infections potentiated by biologics. Infect Dis Clin N Am. 2020;34(2):311–39. https://doi.org/10.1016/j.idc.2020.02.006.CrossRef

28.

Gilenya (Fingolimod) [Prescribing Information]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022527s008lbl.pdf. Revised 2012. Accessed March 9, 2021.

29.

Mayzent (siponimod). [Prescribing Information]. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209884s000lbl.pdf. Revised March 2019. Accessed March 9, 2021.

30.

Zeposia (Ozanimod) [Prescribing Information]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209899s000lbl.pdf. Revised March 2020. Accessed March 9 2021.

31.

• Arvin AM, Wolinsky JS, Kappos L, Morris MI, Reder AT, Tornatore C, et al. Varicella-Zoster Virus Infections in Patients Treated With Fingolimod: Risk Assessment and Consensus Recommendations for Management. JAMA Neurol. 2015;72(1):31–9. https://doi.org/10.1001/jamaneurol.2014.3065. A thorough review of the pathophysiology and risks associated with varicella in the setting of fingolimod.CrossRefPubMedPubMedCentral

32.

Lemtrada (Alemtuzumab). [Prescribing Information]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/103948s5158lbl.pdf. Revised October 2017. Accessed March 9, 2021.

33.

Mavenclad (Cladribine). [Prescribing Information]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022561s000lbl.pdf. Revised March 2019. Accessed March 14, 2021.

34.

Marin M, Güris D, Chaves SS, Schmid S, Seward JF. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2007;56(Rr-4):1–40.PubMed

35.

Ellrichmann G, Bolz J, Peschke M, Duscha A, Hellwig K, Lee D-H, et al. Peripheral CD19+ B-cell counts and infusion intervals as a surrogate for long-term B-cell depleting therapy in multiple sclerosis and neuromyelitis optica/neuromyelitis optica spectrum disorders. J Neurol. 2019;266(1):57–67. https://doi.org/10.1007/s00415-018-9092-4.CrossRefPubMed

36.

Tecfidera (Dimethyl Fumarate). [Prescribing Information]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204063lbl.pdf. Revised March 2013. Accessed March 11, 2021.

37.

Lal H, Cunningham AL, Godeaux O, Chlibek R, Diez-Domingo J, Hwang S-J, et al. Efficacy of an Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults. N Engl J Med. 2015;372(22):2087–96. https://doi.org/10.1056/NEJMoa1501184.CrossRefPubMed

38.

Dooling KL, Guo A, Patel M, Lee GM, Moore K, Belongia EA, et al. Recommendations of the advisory committee on immunization practices for use of herpes zoster vaccines. MMWR Morb Mortal Wkly Rep. 2018;67(3):103–8. https://doi.org/10.15585/mmwr.mm6703a5.CrossRefPubMedPubMedCentral

39.

Shingrix (Zoster Vaccine Recombinant, Adjuvanted). [Prescribing Information]. U.S. Food and Drug Administration website. Accessed March 12, 2021

40.

Kappos L, Mehling M, Arroyo R, Izquierdo G, Selmaj K, Curovic-Perisic V, et al. Randomized trial of vaccination in fingolimod-treated patients with multiple sclerosis. Neurology. 2015;84(9):872–9. https://doi.org/10.1212/wnl.0000000000001302.CrossRefPubMed

41.

Epstein DJ, Dunn J, Deresinski S. Infectious complications of multiple sclerosis therapies: implications for screening, prophylaxis, and management. Open Forum Infect Dis. 2018;5(8):ofy174. https://doi.org/10.1093/ofid/ofy174.CrossRefPubMedPubMedCentral

42.

Tysabri (natalizumab). [Prescribing Information]. U.S. Food and Drug Administration website. https://www.tysabri.com/content/dam/commercial/tysabri/pat/en_us/pdf/tysabri_prescribing_information.pdf. Revised June 2020. Accessed March 9, 2021.

43.

Bafiertam (monomethyl fumarate) [Prescribing Information]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210296s000lbl.pdf. Accessed March 17, 2021.

44.

Perini P, Rinaldi F, Puthenparampil M, Marcon M, Perini F, Gallo P. Herpes simplex virus encephalitis temporally associated with dimethyl fumarate-induced lymphopenia in a multiple sclerosis patient. Mult Scler Relat Disord. 2018;26:68–70. https://doi.org/10.1016/j.msard.2018.09.009.CrossRefPubMed

45.

Hanna J, Prada C, Everage N, Kalari S, Chalkias S, Singhal P, et al. Clinical trial and post-marketing reports indicate no increased risk of herpes zoster in patients treated with delayed-release dimethyl Fumarate (P5.362). Neurology. 2018;90(15 Supplement):P5.362.

46.

Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med. 2016;376(3):209–20. https://doi.org/10.1056/NEJMoa1606468.CrossRefPubMed

47.

Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, et al. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med. 2017;376(3):221–34. https://doi.org/10.1056/NEJMoa1601277.CrossRefPubMed

48.

Luna G, Alping P, Burman J, Fink K, Fogdell-Hahn A, Gunnarsson M, et al. Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies. JAMA Neurol. 2020;77(2):184–91. https://doi.org/10.1001/jamaneurol.2019.3365.CrossRefPubMed

49.

Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goelz S, Natarajan A, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med. 2012;366(20):1870–80. https://doi.org/10.1056/NEJMoa1107829.CrossRefPubMed

50.

Williamson EML, Berger JR. Diagnosis and treatment of progressive multifocal leukoencephalopathy associated with multiple sclerosis therapies. Neurotherapeutics. 2017;14(4):961–73. https://doi.org/10.1007/s13311-017-0570-7.CrossRefPubMedPubMedCentral

51.

Plavina T, Subramanyam M, Bloomgren G, Richman S, Pace A, Lee S, et al. Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol. 2014;76(6):802–12. https://doi.org/10.1002/ana.24286.CrossRefPubMed

52.

•• Ryerson LZ, Foley J, Chang I, Kister I, Cutter G, Metzger RR, et al. Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing. Neurology. 2019;93(15):e1452–e62. https://doi.org/10.1212/wnl.0000000000008243. An important study demonstrating that natalizumab extended interval dosing decreases the risk of PML.CrossRefPubMedPubMedCentral

53.

Ho PR, Koendgen H, Campbell N, Haddock B, Richman S, Chang I. Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies. Lancet Neurol. 2017;16(11):925–33. https://doi.org/10.1016/s1474-4422(17)30282-x.CrossRefPubMed

54.

Schwab N, Schneider-Hohendorf T, Melzer N, Cutter G, Wiendl H. Natalizumab-associated PML. Challenges with incidence, resulting risk, and risk stratification. Neurology. 2017;88(12):1197–205. https://doi.org/10.1212/wnl.0000000000003739.CrossRefPubMed

55.

Baber U, Bouley A, Egnor E, Sloane JA. Anti-JC virus antibody index changes in rituximab-treated multiple sclerosis patients. J Neurol. 2018;265(10):2342–5. https://doi.org/10.1007/s00415-018-8996-3.CrossRefPubMed

56.

Wattjes MP, Rovira À, Miller D, Yousry TA, Sormani MP, de Stefano N, et al. MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis—establishing disease prognosis and monitoring patients. Nat Rev Neurol. 2015;11(10):597–606. https://doi.org/10.1038/nrneurol.2015.157.CrossRefPubMed

57.

Scarpazza C, Signori A, Cosottini M, Sormani MP, Gerevini S, Capra R. Should frequent MRI monitoring be performed in natalizumab-treated MS patients? A contribution to a recent debate. Mult Scler J. 2020;26(10):1227–36. https://doi.org/10.1177/1352458519854162.CrossRef

58.

Chisari CG, Grimaldi LM, Salemi G, Ragonese P, Iaffaldano P, Bonavita S, et al. Clinical effectiveness of different natalizumab interval dosing schedules in a large Italian population of patients with multiple sclerosis. Journal of Neurology, Neurosurgery &amp. Psychiatry. 2020;91(12):1297–303. https://doi.org/10.1136/jnnp-2020-323472.CrossRef

59.

Zhovtis Ryerson L, Frohman TC, Foley J, Kister I, Weinstock-Guttman B, Tornatore C, et al. Extended interval dosing of natalizumab in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2016;87(8):885–9. https://doi.org/10.1136/jnnp-2015-312940.CrossRefPubMed

60.

Klotz L, Havla J, Schwab N, Hohlfeld R, Barnett M, Reddel S, et al. Risks and risk management in modern multiple sclerosis immunotherapeutic treatment. Ther Adv Neurol Disord. 2019;12:1756286419836571. https://doi.org/10.1177/1756286419836571.CrossRefPubMedPubMedCentral

61.

Berger JR, Cree BA, Greenberg B, Hemmer B, Ward BJ, Dong VM, et al. Progressive multifocal leukoencephalopathy after fingolimod treatment. Neurology. 2018;90(20):e1815–e21. https://doi.org/10.1212/wnl.0000000000005529.CrossRefPubMedPubMedCentral

62.

Mills EA, Mao-Draayer Y. Understanding progressive multifocal leukoencephalopathy risk in multiple sclerosis patients treated with immunomodulatory therapies: a bird’s eye view. Front Immunol. 2018;9:138. https://doi.org/10.3389/fimmu.2018.00138.CrossRefPubMedPubMedCentral

63.

Patel A, Sul J, Gordon ML, Steinklein J, Sanguinetti S, Pramanik B, et al. Progressive multifocal leukoencephalopathy in a patient with progressive multiple sclerosis treated with ocrelizumab monotherapy. JAMA Neurol. 2021. https://doi.org/10.1001/jamaneurol.2021.0627.

64.

Parrotta E, Kister I, Charvet L, Sammarco C, Saha V, Charlson RE, et al. COVID-19 outcomes in MS: observational study of early experience from NYU Multiple Sclerosis Comprehensive Care Center. Neurol Neuroimmunol Neuroinflamm. 2020;7(5):e835. https://doi.org/10.1212/nxi.0000000000000835.CrossRefPubMedPubMedCentral

65.

Louapre C, Collongues N, Stankoff B, Giannesini C, Papeix C, Bensa C, et al. Clinical characteristics and outcomes in patients with coronavirus disease 2019 and multiple sclerosis. JAMA Neurol. 2020;77(9):1079–88. https://doi.org/10.1001/jamaneurol.2020.2581.CrossRefPubMed

66.

Sahraian MA, Azimi A, Navardi S, Ala S, Naser MA. Evaluation of the rate of COVID-19 infection, hospitalization and death among Iranian patients with multiple sclerosis. Mult Scler Relat Disord. 2020;46:102472. https://doi.org/10.1016/j.msard.2020.102472.CrossRefPubMedPubMedCentral

67.

Sormani MP, De Rossi N, Schiavetti I, Carmisciano L, Cordioli C, Moiola L, et al. Disease-modifying therapies and coronavirus disease 2019 severity in multiple sclerosis. Ann Neurol. 2021;89:780–9. https://doi.org/10.1002/ana.26028.CrossRefPubMedPubMedCentral

68.

Simpson-Yap S, De Brouwer E, Kalincik T, Rijke N, Hillert J, Walton C et al. Associations of DMT therapies with COVID-19 severity in multiple sclerosis. medRxiv. 2021:2021.02.08.21251316. https://doi.org/10.1101/2021.02.08.21251316.

69.

Gandhi RT, Lynch JB, del Rio C. Mild or Moderate Covid-19. N Engl J Med. 2020;383(18):1757–66. https://doi.org/10.1056/NEJMcp2009249.CrossRefPubMed

70.

Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383:2603–15. https://doi.org/10.1056/NEJMoa2034577.CrossRefPubMed

71.

Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2020;384(5):403–16. https://doi.org/10.1056/NEJMoa2035389.CrossRefPubMed

72.

Sadoff J, Le Gars M, Shukarev G, Heerwegh D, Truyers C, de Groot AM, et al. Interim results of a phase 1–2a trial of Ad26.COV2.S Covid-19 Vaccine. N Engl J Med. 2021. https://doi.org/10.1056/NEJMoa2034201.

73.

Timing MS Medications with COVID-19 mRNA Vaccines. The National Multiple Sclerosis Society. Website https://www.nationalmssociety.org/coronavirus-covid-19-information/multiple-sclerosis-and-coronavirus/covid-19-vaccine-guidance/Timing-MS-Medications-with-COVID-19-Vaccines. Revised March 18, 2021. Accessed March 18, 2021.

74.

Tuberculosis. World Health Organization website. https://www.who.int/news-room/fact-sheets/detail/tuberculosis. Revised October 14, 2020. Accessed March 18, 2021.

75.

Mancuso JD, Diffenderfer JM, Ghassemieh BJ, Horne DJ, Kao TC. The prevalence of latent tuberculosis infection in the United States. Am J Respir Crit Care Med. 2016;194(4):501–9. https://doi.org/10.1164/rccm.201508-1683OC.CrossRefPubMed

76.

Confavreux C, O'Connor P, Comi G, Freedman MS, Miller AE, Olsson TP, et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2014;13(3):247–56. https://doi.org/10.1016/s1474-4422(13)70308-9.CrossRefPubMed

77.

Vermersch P, Czlonkowska A, Grimaldi LM, Confavreux C, Comi G, Kappos L, et al. Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial. Mult Scler J. 2014;20(6):705–16. https://doi.org/10.1177/1352458513507821.CrossRef

78.

O'Connor P, Comi G, Freedman MS, Miller AE, Kappos L, Bouchard JP, et al. Long-term safety and efficacy of teriflunomide: nine-year follow-up of the randomized TEMSO study. Neurology. 2016;86(10):920–30. https://doi.org/10.1212/wnl.0000000000002441.CrossRefPubMedPubMedCentral

79.

Aubagio (Teriflunomide). [Prescribing Information]. U.S. Food and Drug Administration website. https://products.sanofi.us/Aubagio/Aubagio.pdf. Revised November 2020. Accessed March 9, 2021.

80.

Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet. 2012;380(9856):1829–39. https://doi.org/10.1016/s0140-6736(12)61768-1.CrossRefPubMed

81.

Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung HP, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet. 2012;380(9856):1819–28. https://doi.org/10.1016/s0140-6736(12)61769-3.CrossRefPubMed

82.

Bua A, Ruggeri M, Zanetti S, Molicotti P. Effect of teriflunomide on QuantiFERON-TB Gold results. Med Microbiol Immunol. 2017;206(1):73–5. https://doi.org/10.1007/s00430-016-0482-x.CrossRefPubMed

83.

Bouley AJ, Baber U, Egnor E, Samaan S, Sloane JA. Prevalence of latent tuberculosis in the multiple sclerosis clinic and effect of multiple sclerosis treatment on tuberculosis testing. Int J MS Care. 2021;23(1):26–30. https://doi.org/10.7224/1537-2073.2019-015.CrossRefPubMed

84.

Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung H-P, Hemmer B, et al. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med. 2016;376(3):221–34. https://doi.org/10.1056/NEJMoa1601277.CrossRefPubMed

85.

Hauser SL, Bar-Or A, Cohen JA, Comi G, Correale J, Coyle PK, et al. Ofatumumab versus teriflunomide in multiple sclerosis. N Engl J Med. 2020;383(6):546–57. https://doi.org/10.1056/NEJMoa1917246.CrossRefPubMed

86.

Vollmer BL, Wallach AI, Corboy JR, Dubovskaya K, Alvarez E, Kister I. Serious safety events in rituximab-treated multiple sclerosis and related disorders. Ann Clin Transl Neurol. 2020;7(9):1477–87. https://doi.org/10.1002/acn3.51136.CrossRefPubMedPubMedCentral

87.

Roberts DM, Jones RB, Smith RM, Alberici F, Kumaratne DS, Burns S, et al. Rituximab-associated hypogammaglobulinemia: incidence, predictors and outcomes in patients with multi-system autoimmune disease. J Autoimmun. 2015;57:60–5. https://doi.org/10.1016/j.jaut.2014.11.009.CrossRefPubMed

88.

Gottenberg JE, Ravaud P, Bardin T, Cacoub P, Cantagrel A, Combe B, et al. Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry. Arthritis Rheum. 2010;62(9):2625–32. https://doi.org/10.1002/art.27555.CrossRefPubMed

89.

Barmettler S, Ong M-S, Farmer JR, Choi H, Walter J. Association of immunoglobulin levels, infectious risk, and mortality with rituximab and hypogammaglobulinemia. JAMA Netw Open. 2018;1(7):e184169. https://doi.org/10.1001/jamanetworkopen.2018.4169.CrossRefPubMedPubMedCentral

90.

Cohen BA. Late-onset neutropenia following ocrelizumab therapy for multiple sclerosis. Neurology. 2019;92(9):435–6. https://doi.org/10.1212/wnl.0000000000006924.CrossRefPubMed

91.

Auer M, Bsteh G, Hegen H, Wurth S, Zinganell A, Berger T, et al. Late-onset neutropenia in a multiple sclerosis patient after first dose ocrelizumab switched from rituximab. Multiple Sclerosis Related Disorders. 2020;43:102155. https://doi.org/10.1016/j.msard.2020.102155.CrossRefPubMed

92.

Fox EJ, Buckle GJ, Singer B, Singh V, Boster A. Lymphopenia and DMTs for relapsing forms of MS; Considerations for the treating neurologist. Neurol Clin Pract. 2019;9(1):53–63. https://doi.org/10.1212/cpj.0000000000000567.CrossRefPubMedPubMedCentral

93.

Casulo C, Maragulia J, Zelenetz AD. Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections. Clin Lymphoma Myeloma Leuk. 2013;13(2):106–11. https://doi.org/10.1016/j.clml.2012.11.011.CrossRefPubMed

94.

Prairie Collaborative Immune Globulin Utilization Management Framework Project. Criteria for the clinical use of immune globulin. Alberta Ministry of Health, Shared Health Manitoba, and Saskatchewan Ministry of Health. 2018.

95.

Maarouf A, Rico A, Boutiere C, Perriguey M, Demortiere S, Pelletier J, et al. Extending rituximab dosing intervals in patients with MS during the COVID-19 pandemic and beyond? Neurol - Neuroimmunol Neuroinflamm. 2020;7(5):e825. https://doi.org/10.1212/nxi.0000000000000825.CrossRefPubMedPubMedCentral

96.

Willis MD, Harding KE, Pickersgill TP, Wardle M, Pearson OR, Scolding NJ, et al. Alemtuzumab for multiple sclerosis: long term follow-up in a multi-centre cohort. Mult Scler. 2016;22(9):1215–23. https://doi.org/10.1177/1352458515614092.CrossRefPubMed

97.

Gillison ML, Chaturvedi AK, Lowy DR. HPV prophylactic vaccines and the potential prevention of noncervical cancers in both men and women. Cancer. 2008;113(10 Suppl):3036–46. https://doi.org/10.1002/cncr.23764.CrossRefPubMedPubMedCentral

98.

Cervical Cancer: Screening. United States Preventive Services Task Force. Website. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/cervical-cancer-screening. Revised August 21, 2018. Accessed March 26, 2021.

99.

Human Papillomavirus (HPV) Vaccination Information for Clinicians. Centers for disease control and prevention. Website. https://www.cdc.gov/vaccines/vpd/hpv/hcp/index.html. Revised March 17, 2020. Accessed March 26, 2021.

100.

Moiola L, Barcella V, Benatti S, Capobianco M, Capra R, Cinque P, et al. The risk of infection in patients with multiple sclerosis treated with disease-modifying therapies: A Delphi consensus statement. Mult Scler. 2020;1352458520952311:331–46. https://doi.org/10.1177/1352458520952311.CrossRef

101.

Listeria (Listeriosis) Prevention. Centers for disease control and prevention. Website https://www.cdc.gov/listeria/prevention.html. Revised June 17, 2019. Accessed March 26, 2021.

102.

Lemtrada (Alemtuzumab). [Summary of Product Characteristics]. European Medicines Agency Website. https://www.ema.europa.eu/en/documents/product-information/lemtrada-epar-product-information_en.pdf. Accessed March 14, 2021.

103.

Buonomo AR, Zappulo E, Viceconte G, Scotto R, Borgia G, Gentile I. Risk of opportunistic infections in patients treated with alemtuzumab for multiple sclerosis. Expert Opin Drug Saf. 2018;17(7):709–17. https://doi.org/10.1080/14740338.2018.1483330.CrossRefPubMed

104.

Holmøy T, von der Lippe H, Leegaard TM. Listeria monocytogenes infection associated with alemtuzumab - - a case for better preventive strategies. BMC Neurol. 2017;17(1):65. https://doi.org/10.1186/s12883-017-0848-8.CrossRefPubMedPubMedCentral

105.

Yann K, Jackson F, Sharaf N, Mihalova T, Talbot P, Rog D, et al. Acute respiratory distress syndrome following alemtuzumab therapy for relapsing multiple sclerosis. Multiple Sclerosis Related Disord. 2017;14:1–3. https://doi.org/10.1016/j.msard.2017.03.001.CrossRef

106.

Kim SJ, Moon JH, Kim H, Kim JS, Hwang YY, Intragumtornchai T, et al. Non-bacterial infections in Asian patients treated with alemtuzumab: a retrospective study of the Asian Lymphoma Study Group. Leuk Lymphoma. 2012;53(8):1515–24. https://doi.org/10.3109/10428194.2012.659735.CrossRefPubMed

107.

Maertens J, Cesaro S, Maschmeyer G, Einsele H, Donnelly JP, Alanio A, et al. ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients. J Antimicrob Chemother. 2016;71(9):2397–404. https://doi.org/10.1093/jac/dkw157.CrossRefPubMed

108.

Recommended Adult Immunization Schedule for ages 19 years or older, United States, 2021. Centers for Disease Control and Prevention. Website. https://www.cdc.gov/vaccines/schedules/hcp/imz/adult.html. Revised February 12, 2021. Accessed March 25, 2021.

109.

Schwid SR, Decker MD, Lopez-Bresnahan M. Immune response to influenza vaccine is maintained in patients with multiple sclerosis receiving interferon beta-1a. Neurology. 2005;65(12):1964–6. https://doi.org/10.1212/01.wnl.0000188901.12700.e0.CrossRefPubMed

110.

von Hehn C, Howard J, Liu S, Meka V, Pultz J, Mehta D, et al. Immune response to vaccines is maintained in patients treated with dimethyl fumarate. Neurol Neuroimmunol Neuroinflamm. 2018;5(1):e409. https://doi.org/10.1212/nxi.0000000000000409.CrossRef

111.

McCarthy CL, Tuohy O, Compston DAS, Kumararatne DS, Coles AJ, Jones JL. Immune competence after alemtuzumab treatment of multiple sclerosis. Neurology. 2013;81(10):872–6. https://doi.org/10.1212/WNL.0b013e3182a35215.CrossRefPubMedPubMedCentral

112.

Kaufman M, Pardo G, Rossman H, Sweetser MT, Forrestal F, Duda P. Natalizumab treatment shows no clinically meaningful effects on immunization responses in patients with relapsing-remitting multiple sclerosis. J Neurol Sci. 2014;341(1-2):22–7. https://doi.org/10.1016/j.jns.2014.03.035.CrossRefPubMed

113.

Vågberg M, Kumlin U, Svenningsson A. Humoral immune response to influenza vaccine in natalizumab-treated MS patients. Neurol Res. 2012;34(7):730–3. https://doi.org/10.1179/1743132812Y.0000000059.CrossRefPubMed

114.

Ciotti JR, Valtcheva MV, Cross AH. Effects of MS disease-modifying therapies on responses to vaccinations: A review. Mult Scler Relat Disord. 2020;45:102439. https://doi.org/10.1016/j.msard.2020.102439.CrossRefPubMedPubMedCentral

115.

•• Bar-Or A, Calkwood JC, Chognot C, Evershed J, Fox EJ, Herman A, et al. Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis. VELOCE Study. 2020;95(14):e1999–2008. https://doi.org/10.1212/wnl.0000000000010380. This is a timely and rigorous study examining the effect of ocrelizumab on vaccine responses.CrossRef

Titel: Infection Mitigation Strategies for Multiple Sclerosis Patients on Oral and Monoclonal Disease-Modifying Therapies
verfasst von: Tyler Ellis Smith
Ilya Kister
Publikationsdatum: 01.07.2021
Verlag: Springer US
Erschienen in: Current Neurology and Neuroscience Reports / Ausgabe 7/2021
Print ISSN: 1528-4042
Elektronische ISSN: 1534-6293
DOI: https://doi.org/10.1007/s11910-021-01117-y

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Was nützt die Kraniektomie bei schwerer tiefer Hirnblutung?

17.05.2024 Hirnblutung Nachrichten

Eine Studie zum Nutzen der druckentlastenden Kraniektomie nach schwerer tiefer supratentorieller Hirnblutung deutet einen Nutzen der Operation an. Für überlebende Patienten ist das dennoch nur eine bedingt gute Nachricht.

Thrombektomie auch bei großen Infarkten von Vorteil

16.05.2024 Ischämischer Schlaganfall Nachrichten

Auch ein sehr ausgedehnter ischämischer Schlaganfall scheint an sich kein Grund zu sein, von einer mechanischen Thrombektomie abzusehen. Dafür spricht die LASTE-Studie, an der Patienten und Patientinnen mit einem ASPECTS von maximal 5 beteiligt waren.

Schwindelursache: Massagepistole lässt Otholiten tanzen

14.05.2024 Benigner Lagerungsschwindel Nachrichten

Wenn jüngere Menschen über ständig rezidivierenden Lagerungsschwindel klagen, könnte eine Massagepistole der Auslöser sein. In JAMA Otolaryngology warnt ein Team vor der Anwendung hochpotenter Geräte im Bereich des Nackens.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2021

Nutraceuticals and Behavioral Therapy for Headache

Effects of the Menstrual Cycle on Neurological Disorders

Economics of Multiple Sclerosis Disease-Modifying Therapies in the USA

Neurologic Complications of Poverty: the Associations Between Poverty as a Social Determinant of Health and Adverse Neurologic Outcomes

Cluster Headache: A Review and Update in Treatment

Sleep Disorders in Mitochondrial Diseases